Marker Therapeutics (MRKR) AI Stock Analysis

• Market Cap: $18.17M
• Dividend Yield: N/A
• Average Volume (3M): 193.84K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: -12.99%
• EPS Growth: -13.67%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 16,673,126
• 10 Day Avg. Volume: 188,174
• 30 Day Avg. Volume: 193,839
• PEG Ratio: 0.07
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 4.24
• P/FCF Ratio: -2.56
• Enterprise Value/Market Cap: -0.22
• Enterprise Value/Revenue: -0.85
• Enterprise Value/Gross Profit: 0.52
• Enterprise Value/Ebitda: 0.39
• 1Y Price Target: $8.00
• Price Target Upside: 676.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -1.5
• Revenue Forecast (FY): $2.65M

• Rating: 44 Neutral
• Price Target: ―

Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company's ability to manage cash flow and improve operational efficiencies to support future growth.

Positive Factors

Clinical Trial Progress

The positive results from the Phase 1 APOLLO study indicate promising efficacy and safety for MT-601, potentially enhancing Marker Therapeutics' competitive position in the oncology market and supporting future regulatory approvals.

Strong Cash Position

A strong cash position with no debt provides financial stability, allowing Marker Therapeutics to fund ongoing R&D and clinical trials, which is crucial for long-term growth and operational resilience in the biotech industry.

Revenue Growth

Consistent revenue growth through partnerships and collaborations highlights the company's ability to leverage its technology and attract investment, supporting its strategic goals and enhancing its market presence.

Negative Factors

Profitability Challenges

Persistent profitability challenges due to high net losses and negative margins could hinder Marker Therapeutics' ability to sustain operations without external funding, impacting long-term financial health and investor confidence.

Negative Cash Flow

Negative cash flow indicates a reliance on external funding, which poses financial risks if capital markets become less accessible, potentially affecting the company's ability to invest in R&D and clinical advancements.

High R&D Expenses

Rising R&D expenses without corresponding revenue growth can strain financial resources, necessitating efficient capital allocation to ensure continued development and commercialization of therapeutic candidates.

Marker Therapeutics Business Overview & Revenue Model

Company Description

Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company specializing in the development of innovative cell therapies for the treatment of hematological malignancies and solid tumors. The company's proprietary technology, MultiTAA-specific T cell therapy, is designed to selectively target tumor-associated antigens, offering a potentially more effective and safer alternative to conventional cancer treatments. Marker Therapeutics is focused on advancing its lead product candidates through clinical trials to address unmet medical needs in cancer care.

How the Company Makes Money

Marker Therapeutics generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future product sales. Additionally, the company may receive funding from grants and research agreements to support the development of its therapeutic candidates. As a clinical-stage company, Marker Therapeutics does not yet generate revenue from product sales, as its products are still undergoing clinical trials and have not yet received regulatory approval for commercialization.

Marker Therapeutics Financial Statement Overview

Summary

Marker Therapeutics shows promising revenue growth but struggles with profitability and cash flow management. The strong cash position provides a buffer, yet the company must focus on improving operational efficiencies and reducing losses to enhance financial health and attract sustainable investment.

Income Statement

Marker Therapeutics has demonstrated consistent revenue growth over the years, culminating in a significant increase in TTM (Trailing-Twelve-Months) revenue. However, this growth is overshadowed by substantial net losses and negative EBIT and EBITDA margins, indicating persistent profitability challenges.

Balance Sheet

The company maintains a strong cash position with zero debt as of the latest report, which enhances its financial stability. However, the negative equity ratio over time and significant net losses are concerning, reflecting a need for improved operational efficiency.

Cash Flow

Marker Therapeutics is experiencing negative operating and free cash flow, indicating cash burn which is common in early-stage biotechs. The positive financing cash flow suggests external funding reliance, which could pose future financial risks if not managed properly.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.69M	6.59M	3.31M	3.51M	1.24M	466.79K
Gross Profit	-7.70M	-6.88M	-7.11M	-8.45M	-1.92M	-18.41M
EBITDA	-10.12M	-11.12M	-11.79M	-17.00M	-38.72M	-27.63M
Net Income	-14.30M	-10.73M	-8.24M	-29.93M	-41.88M	-28.71M
Balance Sheet
Total Assets	21.73M	22.02M	17.13M	34.42M	68.14M	45.61M
Cash, Cash Equivalents and Short-Term Investments	17.59M	19.19M	15.11M	11.78M	42.35M	21.35M
Total Debt	0.00	0.00	0.00	7.62M	11.87M	12.26M
Total Liabilities	3.35M	3.46M	3.07M	14.82M	24.15M	18.27M
Stockholders Equity	18.39M	18.56M	14.05M	19.60M	43.99M	27.34M
Cash Flow
Free Cash Flow	-14.82M	-10.91M	-16.44M	-26.97M	-30.41M	-29.29M
Operating Cash Flow	-14.82M	-10.91M	-16.44M	-26.97M	-27.28M	-20.03M
Investing Cash Flow	0.00	0.00	18.66M	-4.95M	-3.13M	-9.25M
Financing Cash Flow	24.76M	14.99M	1.11M	202.13K	52.56M	6.74M

Marker Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.03
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MRKR, the sentiment is Positive. The current price of 1.03 is above the 20-day moving average (MA) of 0.96, above the 50-day MA of 0.97, and below the 200-day MA of 1.25, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 61.87 is Neutral, neither overbought nor oversold. The STOCH value of 77.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MRKR.

Marker Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MBRX	44 Neutral	$24.59M	-0.11	―	―	―	79.31%
MRKR	44 Neutral	$18.17M	―	-110.67%	―	-12.99%	-13.67%
ADXN	44 Neutral	$10.43M	―	-61.65%	―	-80.31%	-293.92%
IBIO	43 Neutral	$24.74M	―	-54.50%	―	185.71%	79.03%
ABVC	43 Neutral	$68.53M	-12.64	-40.32%	―	56.52%	75.22%
ALLR	28 Underperform	$17.86M	-0.13	-122.61%	―	―	99.82%

Marker Therapeutics Corporate Events

Marker Therapeutics Grants Stock Options to Directors

On February 12, 2024, Marker Therapeutics’ Board of Directors approved a discretionary award of 30,000 stock options to each of three non-employee directors. These stock options vest annually over three years, aligning with the company’s strategic compensation plan to incentivize leadership and potentially enhance company performance.